The Underutilization of Intrathecal Baclofen in Poststroke Spasticity

REFERENCES

• Heart Disease and Stroke Statistics 2010 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation. 2010;121:e46–e215.
   Google Scholar
• Neyer JR, Greenlund KJ, Denny CH, et al. Prevalence of stroke - United States, 2005. MMWR. 2007;56(19):469–474.
   PubMedGoogle Scholar
• Bejot Y, Benatru I, Rouaud O, et al. Epidemiology of stroke in Europe: geographic and environmental differences. I Neurol Sci. 2007;262:85–88.
   PubMed Web of Science ®Google Scholar
• Gentil A, Bejot L, Lorgis L, et al. Comparative epidemiology of stroke and acute myocardial infarction: the Dijon vascular project (Diva). I Neurol Neurosurg Psychiatry. 2009; 80:1006–1011.
   PubMed Web of Science ®Google Scholar
• One degree of separation: paralysis and spinal cord injury in the United States. The Christopher & Dana Reeve Foundation's Paralysis Resource Center (PRC). 2009. http://www.christopherreeve.org
   Google Scholar
• Sheean G. Neurophysiology of spasticity. In: Barnes MP, Johnson GR. Upper Motor Neuron Syndrome and Spasticity. Cambridge University Press; 2001:12–78.
   Google Scholar
• Lance J. Symposium synopsis in spasticity. In: Feldman R, Young R, Koella W. Disordered Motor Control. Chicago: YearBook Medical Publishers; 1980:487–489.
   Google Scholar
• Gormley ME Jr, O'Brien CF, Yablon SA. A clinical overview of treatment decisions in the management of spasticity. Muscle Nerve. 1997;6(Suppl):S14–20.
   PubMedGoogle Scholar
• Rerny-Neris O, Tiffreau V, Bouilland S, Bussel B. Intrathecal baclofen in subjects with spastic hemiplegia: assessment of the antispastic effect during gait. Arch Phys Med Rehabil. 2003;84: 643–650.
   PubMed Web of Science ®Google Scholar
• Bohannon RW, Smith MB. Interrater reliability of a modified Ashworth scale of muscle spasticity. Phys Ther. 1987;67:2006–2007.
   Google Scholar
• Gregson JM, Leathley MJ, Moore AP, Smith TL, Sharma AK, Watkins CL. Reliability of measurements of muscle tone and muscle power in stroke patients. Age Ageing. 2000;29:223–228.
   PubMed Web of Science ®Google Scholar
• Watkins CL, Leathley MJ, Gregson JM, Moore AP, Smith TL, Sharma AK. Prevalence of spasticity post stroke. Clin Rehabil. 2002;16:515–522.
   PubMed Web of Science ®Google Scholar
• Barnes SA, Gregson JM, Leathley MJ, Sharma AK, Smith TL, Watkins CL. Development and inter-rater reliability of an assessment scale to measure abnormal tone in adult, hemiplegic stroke patients. Physiotherapy. 1999;85:405–409.
   Google Scholar
• Sommerfeld DK, Eek EU, Svensson AK, Holmqvist LW, von Arbin MH. Spasticity after stroke its occurrence and association with motor impairments and activity limitations. Stroke. 2004;35:134–140.
   PubMed Web of Science ®Google Scholar
• Welmer AK, von Arbin M, Widen Holmqvist L, Sommerfeld DK. Spasticity and its association with functioning and health-related quality of life 18 months after stroke. Cerebrovasc Dis. 2006;21: 247–253.
   PubMed Web of Science ®Google Scholar
• Lundstrom E, Terent A, Borg J. Prevalence of disabling spasticity 1 year after first-ever stroke. Eur Neurol. 2008;15:533–539.
   Web of Science ®Google Scholar
• Moura RCR, Fukujima MM, Aguiar AS, et al. Predictive factors for spasticity among ischemic stroke patients. Arq Neuro-Psiquiatr. 2009;67: 1029–1036.
   PubMed Web of Science ®Google Scholar
• Urban PP, Wolf T, Uebele M, et al. Occurrence and clinical predictors of spasticity after ischemic stroke. Stroke. 2010;41:2016–2020.
   PubMed Web of Science ®Google Scholar
• Mahoney Ii, Barthel DW. Functional evaluation: Barthel Index. Md State Med J. 1965;14:61–65.
   PubMedGoogle Scholar
• Wade DT, Hewer RL. Function abilities after stroke: measurement, natural history and prognosis. Neurol Neurosurg Psychiatry. 1987;50:177–182.
   PubMed Web of Science ®Google Scholar
• Collen FM, Wade DT, Robb GF, Bradshaw CM. The Rivermead Mobility Index: a further development of the Rivermead Motor Assessment. Int Disabil Stud. 1991;13:50–54.
   PubMedGoogle Scholar
• Heller A, Wade DT, Wood VA, Sunderland A, Hewer RL, Ward E. Arm function after stroke; measurement and recovery over the first three months. I Neurol Neurosurg Psychiatry. 1987;50:714–719.
   PubMed Web of Science ®Google Scholar
• Lindmark B. Evaluation of functional capacity after stroke with special emphasis on motor function and activities of daily living. Scand I Rehabil Med Suppl. 1988;21:1–40.
   Google Scholar
• Mathias S, Nayak US, Isaacs B. Balance in elderly patients: the "Get-Up and Go" test. Arch Phys Med Rehabil. 1986;67:387–389.
   PubMed Web of Science ®Google Scholar
• Kasner SE. Clinical interpretation and use of stroke scales. Lancet Neurol. 2006;5:603–612.
   PubMed Web of Science ®Google Scholar
• Sullivan M, Karlsson J, Ware J. The Swedish SF-36 Health Survey. Evaluation of data quality, scaling assumptions, reliability, and construct validity across general populations in Sweeden. Soc Sci Med. 1995;41:1349–1358.
   PubMed Web of Science ®Google Scholar
• EuroQoL Group. EuroQoL-A new facility for the measurement of health-related quality of life. Health Policy. 1990;16:199–208.
   PubMed Web of Science ®Google Scholar
• Saulino M, Jacobs BW. The pharmacological management of spasticity. I Neuorsci Nurs. 2006;38:456–459.
   PubMedGoogle Scholar
• Montane E, Vallano A, Laporte JR. Oral antispastic drugs in nonprogressive neurologic diseases: a systematic review. Neurology 2004;63:1357–1363.
   PubMed Web of Science ®Google Scholar
• Katz RT. Management of spasticity. Am I Phys Med Rehabil. 1988;67:108–116.
   PubMed Web of Science ®Google Scholar
• Ward A, Chaffman MO, Sorkin EM. Dantrolene: a review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in malignant hyperthermia, the neuroleptic malignant syndrome and an update of its use in muscle spasticity. Drugs. 1986;32:130–168.
   PubMed Web of Science ®Google Scholar
• Meythaler JM, Guin-Renfroe S, Johnson A, Brunner RM. Prospective assessment of tizanidine for spasticity due to acquired brain injury. Arch Phys Med Rehabil. 2001;82:1155–1163.
   PubMed Web of Science ®Google Scholar
• Francisco GE. Botulinum toxin for post-stroke spastic hypertonia: a review of its efficacy and application in clinical practice. Ann Acad Med Singapore. 2007;36:22–30.
   PubMed Web of Science ®Google Scholar
• Rosales RL, Chua-Yap AS. Evidence-based systemic review on the efficacy and safety of botulinum toxin-A therapy in post-stroke spasticity. I Neural Transum. 2008;115:617–623.
   PubMed Web of Science ®Google Scholar
• Elia AE, Filippini G, Calandrella D, Albanese A. Botulinum neurotoxins for post-stroke spasticity in adults: a systematic review. Movement Disord. 2009;24:801–812.
   PubMed Web of Science ®Google Scholar
• Simpson DM, Gracies JM, Yablon SA, Barbano R, Brashear A. Botulinum neurotoxin versus tizanidine in upper limb spasticity: a placebo-controlled study. I Neurol Neurosurg Psychiatry. 2009;80:380–385.
   PubMed Web of Science ®Google Scholar
• Sheean G. Botulinum toxin should be first-line treatment for poststroke spasticity. I Neurol Neurosurg Psychiatry 2009;80:359.
   PubMed Web of Science ®Google Scholar
• Childers MK, Brashear A, Jozefczyk P, et al. Dose-dependent response to intramuscular botulinum toxin type A for upper-limb spasticity in patients after a stroke. Arch Phys Med Rehabil 2004;85: 1063–1069.
   PubMed Web of Science ®Google Scholar
• Pittock SJ, Moore AP, Hardiman O, et al. A double-blind randomized placebo-controlled evaluation of three doses of botulinum toxin type A (Dysport) in the treatment of spastic equinovarus deformity after stroke. Cerebrovasc Dis. 2003;15:289–300.
   PubMed Web of Science ®Google Scholar
• Smith SJ, Ellis E, White S., Moore AR A double-blinded placebo-controlled study of botulinum toxin in upper limb spasticity after stroke or head injury. Clin Rehabil. 2000;14:5–13.
   PubMed Web of Science ®Google Scholar
• van Kuijk AA, Geurts AC, Bevaart BJ., van Limbeek J. Treatment of upper extremity spasticity in stroke patients by focal neuronal or neuromuscular blockade: a systematic review of the literature. I Rehabil Med. 2002;34:51–61.
   Google Scholar
• Francisco, GE. Intrathecal baclofen in the management of post-stroke hypertonia: current applications and future directions. Acta Neurochir Suppl. 2007;97(1):219–226.
   PubMedGoogle Scholar
• Brashear A, Mayer N. Dose and administration of botulinum toxin for muscle overactivity in adults with an upper motor neuron syndrome. In: Spasticity and Other Forms of Muscle Overactivity in the Upper Motor Neuron Syndrome. WE MOVE; 2008:207–218.
   Google Scholar
• Penn RD, Kroin JS. Continuous intrathecal baclofen for severe spasticity. Lancet. 1985;2:125–127.
   PubMed Web of Science ®Google Scholar
• Albright AL, Cervi A, Singletary J. Intrathecal baclofen for spasticity in cerebral palsy. JAMA. 1991;265:1418–1422.
   PubMed Web of Science ®Google Scholar
• Saltuari L, Kronenberg M, Marosi M, et al. Long-term intrathecal baclofen treatment in supraspinal spasticity. Acta Neurol. 1992;47:195–207.
   Google Scholar
• Meythaler JM, DeVivo MJ, Hadley M. Prospective study on the use of bolus intrathecal baclofen for spastic hypertonia due to acquired brain injury. Arch Phys Med Rehabil. 1996;77:461–466.
   PubMed Web of Science ®Google Scholar
• Becker R, Alberti O, Bauer BL. Continuous intrathecal baclofen infusion in severe spasticity after traumatic or hypoxic brain injury. I Neurol. 1997; 244:160–166.
   Google Scholar
• Meythaler JM, Guin-Renfroe S, Brunner RC, Hadley MN. Intrathecal baclofen for spastic hypertonia from stroke. Stroke. 2001;32:2099–2109.
   PubMed Web of Science ®Google Scholar
• Francisco GE, Boake C. Improvement in walking speed in poststroke spastic hemiplegia after intrathecal baclofen therapy: a preliminary study. Arch Phys Med Rehabil. 2003;84:1194–1199.
   PubMed Web of Science ®Google Scholar
• Ivanhoe CB, Francisco GE, McGuire JR, Su bramanian T, Grissom SR Intrathecal baclofen management of poststroke spastic hypertonia: implications for function and quality of life. Arch Phys Med Rehabil. 2006;87:1509–1515.
   PubMed Web of Science ®Google Scholar
• Data from Medtronic, Inc. Written communication. December 2010.
   Google Scholar
• Francisco, GE. Editorial comment: Can intrathecal baclofen therapy unleash functional recovery after stroke? Stroke. 200132:2018-2019.
   Google Scholar
• Meythaler, J M. Guin-Renfroe, S. Hadley, M N. Continuously infused intrathecal baclofen for spastic/dystonic hemiplegia: a preliminary report. Am J Phys Med Rehabil. 1999;78:247–254.
   PubMed Web of Science ®Google Scholar
• Veltri EP, Mower MM, Reid PR. Twiddler's syndrome: a new twist. PACE. 1984;7:1004–1009.
   Google Scholar
• Bayless CE, Beanlands DS, Baird RJ. The Pacemaker-Twiddler's syndrome: a new complication of implantable transvenous pacemakers. Can Med Assoc J. 1968;99:371–373.
   PubMed Web of Science ®Google Scholar
• Francisco GE, Yablon, SA, Schiess MC, VViggs L, Cavalier S, Grissom S. Consensus panel guidelines for the use of intrathecal baclofen therapy in poststroke spastic hypertonia. Top Stroke Rehabil. 2006;13(4):74–85.
   PubMed Web of Science ®Google Scholar
• Kofler M, Kronenberg MF, Rifici C, Saltuari L, Bauer G. Epileptic seizures associated with intrathecal baclofen application. Neurology. 1994;44: 25–27.
   PubMed Web of Science ®Google Scholar
• Schuele SU, Kellinghaus C, Shook SJ, Bolius N, Bethoux FA, Loddnekemper T. Incidence of seizures in patients with multiple sclerosis treated with intrathecal baclofen. Neurology 2005;64: 1086–1087.
   PubMed Web of Science ®Google Scholar
• Gwartz, BL. Intrathecal baclofen for spasticity caused by thrombotic stroke. Am I Phys Med Rehabil. 2001;80:383–387.
   PubMed Web of Science ®Google Scholar
• Meythaler JM, McCary A, Hadley MN. Prospective assessment of continuous intrathecal infusion of baclofen for spasticity caused by acquired brain injury: a preliminary report. I Neurosurg. 1997;87: 415–419.
   PubMed Web of Science ®Google Scholar
• Knuttson E, Lindblom U, Martensson A. Plasma and cerebrospinal fluid levels of baclofen (Lioresal) at optimal therapeutic responses in spastic paresis. I Neurol Sci. 1974;23:473–484.
   PubMed Web of Science ®Google Scholar
• McCall TD, MacDonald JD. Cervical catheter tip placement for intrathecal baclofen administration. Neurosurgery. 2006;59:634–640.
   PubMed Web of Science ®Google Scholar
• Bernards CM. Cerebrospinal fluid and spinal cord distribution of baclofen and bupivacaine during slow intrathecal infusion in pigs. Anesthesiology. 2006;105:169–178.
   PubMed Web of Science ®Google Scholar
• Albright AL, Thompson K, Carlos S, Minnigh MB. Cerebrospinal fluid baclofen concentrations in patients undergoing continuous intrathecal baclofen therapy. Develop Med Child Neurol. 2007;49:423–425.
   PubMed Web of Science ®Google Scholar
• Saval A, Chiodo AE. Effect of intrathecal baclofen concentration on spasticity control: case series. Spinal Cord Med. 2008;31:394–397.
   PubMed Web of Science ®Google Scholar
• Kofler M, Quirbach E, Schauer R, Singer M, Saltuari L. Limitations of intrathecal baclofen for spastic hemi paresis following stroke. Neurorehabil Neural Repair. 2009;23:26–31.
   PubMed Web of Science ®Google Scholar
• Mayr A, Kofler M, Quirbach E, Matzak H, Frohlich K, Saltuari L. Prospective, blinded, randomized crossover study of gait rehabilitation in stroke patients using the Lokomat gait orthosis. Neurorehabil Neural Repair. 2007;21:307–314.
   PubMed Web of Science ®Google Scholar
• Lord SE, Halligan PW, Wade DT. Visual gait analysis: the development of a clinical assessment and scale. Clin Rehabil. 1998;12:107–119.
   PubMed Web of Science ®Google Scholar
• Horn TS, Yablon SA, Stokic DS. Effect of intrathecal baclofen bolus injection on temporospatial gait characteristics in patients with acquired brain injury. Arch Phys Med Rehabil. 2005;86:1127–1133.
   PubMed Web of Science ®Google Scholar